IVIG versus Plasma Exchange for Guillain-Barré Syndrome: Two Patients, the Same Evidence Base
Two patients with the same syndrome, treated under genuine equipoise between IVIG and plasma exchange. What changes the answer isn't new evidence — it's a comorbidity profile that turns a theoretical risk into a real one.
J.H., a 34-year-old warehouse forklift operator, spent two weeks fighting what he assumed was ordinary food poisoning — a diarrheal illness that resolved on its own — before his legs started giving out from underneath him on the job, first as heaviness climbing a loading ramp, then as an outright stumble that sent a coworker to call for help. Over four days the weakness climbed from his feet to his thighs, symmetric and progressive, and by the time he reached the emergency department his deep tendon reflexes were absent throughout and mild facial weakness had appeared. Stool studies drawn on admission confirmed Campylobacter jejuni, the pathogen most classically linked to the molecular mimicry that triggers Guillain-Barré syndrome, in which antibodies raised against the bacterium's surface structures cross-react with peripheral nerve gangliosides. His forced vital capacity, at 68% predicted, is low enough to watch closely but not yet low enough to need ventilatory support. He has no other medical history — no diabetes, no kidney disease, no vascular risk factors — and normal renal function on admission labs.
The treatment decision itself is settled at the level of "should he receive immunotherapy" but genuinely open at the level of which one. The Dutch GBS trial — van der Meché and Schmitz, 1992 — and the Cochrane reviews built on it since, found IVIG and plasma exchange equally effective across most measured outcomes — neither has emerged as superior in head-to-head comparison. For J.H. specifically, with normal renal function, good peripheral IV access, and no comorbidity that would make either therapy riskier than the other, the choice comes down to logistics rather than a clinical tiebreaker his own presentation supplies.
For J.H. I'd go with IVIG. van der Meché and Schmitz's Dutch GBS trial in 1992 found IVIG at least as effective as plasma exchange, with fewer complications, and the Cochrane evidence since has held that equivalence, and with nothing in his history pushing toward one or the other, the simpler logistics matter — a peripheral IV line versus an apheresis unit and, typically, a central line. There's no reason to add procedural complexity when the outcomes evidence doesn't favor it.
I agree with IVIG here, and for the same underlying reason — I just want to name explicitly why it's a genuinely easy call for him specifically. IVIG's real downside, osmotic renal injury and a real thrombotic risk, particularly with older sucrose-containing formulations and in patients with pre-existing vascular disease, simply isn't in play for J.H. His renal function is normal and he has no vascular risk factors, so the theoretical downside that would make me argue for PLEX in a different patient doesn't apply to him.
I'd push back slightly on framing this as purely a logistics tiebreaker, though, since that undersells why the two options are actually equivalent here rather than just equally convenient. It's not that the risk profile difference doesn't matter and logistics wins by default — it's that IVIG's specific risk (renal injury, thrombosis) genuinely isn't present in this patient, which is a clinical judgment, not just a scheduling one.
Agreed on IVIG for J.H. — and I think it's worth being explicit that this isn't a case where PLEX was ruled out, it's a case where genuine equipoise resolved toward the simpler option because nothing in his profile changed the calculus. That distinction matters for how we frame the next patient, where it won't resolve the same way.
Resolved: IVIG started, chosen on logistic grounds under genuine equipoise. All three voices concurred without disagreement for this patient specifically.
E.S., a 67-year-old retired postal worker, has managed type 2 diabetes for twelve years and chronic kidney disease that has crept from watchful monitoring to a firmly stage-3 label over the past several of them, alongside peripheral vascular disease that already limits how far she can walk before her legs cramp with claudication. She lives alone since her husband's death two years ago, and it was a neighbor who found her on the kitchen floor, unable to push herself back up, that brought her to the emergency department. Ten days before admission she had a diarrheal illness she never had tested; by the time ascending, symmetric weakness reached her hands, her antecedent infection had already resolved and stool studies were no longer useful. Her deep tendon reflexes are absent throughout, and her forced vital capacity, at 61% predicted and trending downward, is lower than J.H.'s was at the same disease stage. Her baseline creatinine runs 1.8, eGFR 38 — real, established kidney disease, not a borderline finding.
The same evidence base that made J.H.'s choice a coin flip makes E.S.'s choice load-bearing in the opposite direction. IVIG's real risk profile — osmotic renal injury from the sucrose or other stabilizing excipients in some formulations, and a genuine, described thrombotic risk — concentrates specifically in patients with pre-existing renal impairment and vascular disease, which is exactly E.S.'s profile on both counts. Plasma exchange carries its own real logistic cost — central line placement, hemodynamic monitoring during fluid shifts — but doesn't carry the renal-specific risk IVIG does. Her difficult peripheral access means a central line is likely needed for either therapy anyway, removing the one practical argument that made IVIG the easier default for J.H.
I'll admit my default reasoning from J.H.'s case doesn't transfer cleanly here. My instinct toward simplicity was really an instinct toward avoiding unnecessary procedural risk when nothing pushes otherwise — but E.S. needs a central line either way given her access, so IVIG's usual logistic advantage isn't actually available to her. Given that, I'd defer to whichever of you weighs the renal risk more directly.
For E.S. specifically, I'd choose PLEX over IVIG, and this is the patient where that renal/thrombotic risk profile I mentioned as theoretical for J.H. becomes the actual deciding factor. She has stage 3 chronic kidney disease and established vascular disease — exactly the population in whom IVIG's osmotic renal injury risk is described, and exactly the population where adding a thrombotic insult on top of existing peripheral vascular disease carries real, not hypothetical, consequence.
This isn't a reversal of my position on J.H., it's the same reasoning applied to different facts — the risk I named as absent for him is the risk I'm naming as present for her, which is exactly what genuine equipoise is supposed to mean: the right answer tracks the patient, not a fixed protocol default.
Agreed on PLEX for E.S. Since a central line is needed regardless of which therapy we choose — her access alone requires it — the logistic argument that resolved J.H.'s case toward IVIG doesn't apply here at all, which removes the tiebreaker in IVIG's favor and leaves the renal-risk argument to decide it cleanly toward PLEX instead.
Resolved: plasma exchange started via central line, with nephrology co-managing given her baseline chronic kidney disease. All three voices converged once E.S.'s specific comorbidity profile was weighed against the same evidence base used for J.H.
Explicitly not treated as evidence that PLEX is generally preferable in GBS — the record is deliberately kept as two patients, same disease, same evidence base, opposite outcomes, to avoid either therapy being read as a default.